The effectiveness of omalizumab in severe atopic bronchial asthma in young patients: clinical cases from real practice
- Autores: Peredelskaya M.Y.1, Nenasheva N.M1
-
Afiliações:
- Russian Medical Academy of Continuous Professional Education
- Edição: Volume 26, Nº 11 (2019)
- Páginas: 101-106
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312294
- DOI: https://doi.org/10.18565/pharmateca.2019.11.101-W6
- ID: 312294
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Patients with severe bronchial asthma (SBA) are refractory to traditional therapy; they have a high frequency of asthma exacerbations, unplanned visits to the doctor and seeking emergency medical care, hospitalizations. Currently, genetically engineering biological preparations have appeared for these patients, the first of which was omalizumab, a recombinant monoclonal antibody to immunoglobulin E. In the world and in our country, quite a lot of experience has been gained with the use of omalizumab in allergic SBA, but local clinical experience of using the drug is still of interest. This article is devoted to the experience of using omalizumab in two young patients with allergic SBA, who managed to get a pronounced improvement in lung function, as well as a significant improvement in the quality of life.
Palavras-chave
Texto integral
Sobre autores
M. Peredelskaya
Russian Medical Academy of Continuous Professional Education
Email: concy1984@gmail.com
Teaching Assistant, Department of Allergology and Immunology
N. Nenasheva
Russian Medical Academy of Continuous Professional Education
Bibliografia
- GINA 2019 https://ginasthma.org/wp-content/ uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf.
- Bousquet J., Mantzouranis E., Cruz A.A., et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J. Allergy Clin Immunol. 2010;126(5):926-38. Doi: 10.1016/j. jaci.2010.07.019.
- Chung K.F., Wenzel S., Brozek J., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-73. doi: 10.1183/09031936.00202013.
- Braunstahl G.J., Chen C.W., Maykut R., et al. The real-world effectiveness of omalizumab in allergic asthma: results from the 2-year eXpeRience registry. Respir Med. 2013;107:1141-51. doi: 10.1016/j.rmed.2013.04.017.
- Eisner M.D., Zazzali J.L., Miller M.K., et al. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS study. J. Asthma. 2012;49:642-48. doi: 10.3109/02770903.2012.690477.
- Alhossan A., Lee C.S., MacDonald K., Abraham I. «Real-life» Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. J. Allergy Clin Immunol Pract. 2017;5(5):1362-70. Doi: 10.1016/j. jaip.2017.02.002.
- Di Bona D., Fiorino I., Taurino M., et al. Long- term ‘real life' safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study Respir Med 2017;130:55-60. Doi: 10.1016/j. rmed.2017.07.013.
- Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. Российское Респираторное общество, 2019. http://spulmo. ru/upload/kr_bronhastma_2019. pdf.
- The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22(3):470-77. doi: 10.1183/09031936.03.00261903.
- Moore W.C., Meyers D.A., Wenzel S.E., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J. Respir Crit Care Med. 2010;181:315-23. doi: 10.1164/rccm.200906-0896CC.
- Schatz M., Hsu J.W., Zeiger R.S., et al. Phenotypes determined by cluster analysis in severe difficult-to treat asthma. J. Allergy Clin. Immunol. 2014;133:1549-56. Doi: 10.1016/j. jaci.2013.10.006.
- Сергеева ГР, Емельянов А.В., Коровина О.В. и др. Тяжелая бронхиальная астма: характеристика пациентов в клинической практике. Терапевтический архив. 2015;12:22-7. doi: 10.1136/thx.2010,153643.
- Ненашева Н.М. Омализумаб в терапиии тяжелой бронхиальной астмы. Эффективная фар макотерапия. Пульмонология и оториноларингология. 2014;2:24-35.
- Roth M., Zhong J., Zumkeller S., et al. The Role of IgE-Receptors in IgE-Dependent Airway Smooth Muscle Cell Remodelling. PLoS One. 2013;8(2):e56015. Doi: https://doi. org/10.1371/journal.pone.0056015.
- Fox H. Anti-IgE in severe persistent allergic asthma. Respirol. 2007;12(Suppl. 3):22-8. doi: 10.1111/j.1440-1843.2007.01016.x
- Novak N., Tepel C., Koch S., Brix K., Bieber T., Kraft S. Evidence for a differential expression of the FcsRIy chain in dendritic cells of atopic and non atopic donors. J. Clin Invest. 2003;111:1047-56. doi: 10.1172/JCI15932.
- Massanari M., Holgate S.T., Busse W.W., et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med. 2010;104(2):188-96. doi: 10.1016/j.rmed.2009.09.011.
- Djukanovic R., Wilson S.J., Kraft M., et al. Effects of treatment with anti-immunoglobulin E. antibody omalizumab on airway inflammation in allergic asthma. Am J. Respir Crit Care Med. 2004;170(6):583-93. Doi: 10.1164/ rccm.200312-165WC.
- GINA Pocket Guide, "Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. V. 2.0, April 2019". https://ginasthma.org/severeasthma.
Arquivos suplementares
